Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating for Alnylam Pharmaceuticals, maintaining a price target of $220.
October 11, 2024 | 5:12 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating for Alnylam Pharmaceuticals, with a maintained price target of $220.
The reiteration of a Neutral rating and maintenance of the price target suggests no significant change in the analyst's outlook on Alnylam Pharmaceuticals. This indicates stability in the stock's perceived value, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100